2007: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's: Clinical Aspects and Therapeutics II
Search or Browse by Day

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's: Clinical Aspects and Therapeutics II

1193
Scleroderma in a Population-based Sample: Evidence Suggests Increasing Incidence
1194
Gastric Antral Vascular Ectasia (GAVE) in Patients with Systemic Sclerosis (SSc): a Systematic Review of the Literature
1195
Serum Interleukin-15 (IL-15) in Patients with Early Systemic Sclerosis
1196
Early Atherosclerosis in Systemic Sclerosis and Its Relation to Disease or Traditional Risk Factors
1197
Assessment of Unmet Needs in the Design of Randomized Controlled Trials and the Lack of Generalizability for Scleroderma Treatment
1198
High Sensitivity C Reactive Protein as a Disease Marker in Systemic Sclerosis
1199
Long-term Effects of Bosentan Treatment on Survival in Patients with Pulmonary Arterial Hypertension (PAH) Related to Connective Tissue Disease (CTD)
1200
Correlations of Subjective Ratings of Dyspnea with Traditional Measures of Parenchymal Lung Disease in Systemic Sclerosis (SSc) with Interstitial Lung Disease (ILD)
1201
Time to Diagnosis in Systemic Sclerosis: Is Gender a Factor?
1202
Familial Clustering of Auto-immune Diseases in Patients with Systemic Sclerosis
1203
Early Detection of the Transition from Primary to Secondary Raynaud's Phenomenon by Videocapillaroscopy
1204
Influence of Sex and Race on Clinical and Immunological Manifestations In Systemic Sclerosis: Analysis Of 1139 Brazilian Patients
1205
Efficacy of Complementary Cardiac MRI with Cine MRI, Pharmacological Stress Perfusion and Late Enhancement in Asymptomatic Patients with Systemic Sclerosis
1206
N-Terminal Pro-Brain Natriuretic Peptide as a Diagnostic Marker of Pulmonary Artery Hypertension in Connective Tissue Disease
1207
Lupus Nephritis in Patients with Longstanding Limited Scleroderma: A Report of Two Patients
1208
Pulmonary Hypertension (PH)-Assessment and Recognition of Outcomes in Scleroderma (Systemic Sclerosis, SSc): PHAROS
1209
Bosentan Increases Serum Il-12 Levels in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension
1210
Serum levels of Endoglin in patients with Systemic Sclerosis and Pulmonary Arterial Hypertension
1211
Improvement of Gastric Antral Vascular Ectasia (GAVE) in Systemic Sclerosis Patients With Cyclophosphamide
1212
The Eustar Prospective Follow-Up Study of Systemic Sclerosis Patients with Barrett's Esophagus: Baseline Analysis of Dysplasia
1213
C-type Natriuretic Peptide (cnp) and Nt-pro-cnp in Raynaud’S Phenomenon: Disease Severity Markers?
1214
Galectins -1 And -3 Expression in Lesional Skin of Patients with Progressive Systemic Sclerosis
1215
Stimulatory Antibodies to Vascular Receptors in Systemic Sclerosis
1216
A Transforming Growth Factor-β (TGFβ)-Responsive Gene Signature Predicts More Severe Skin Disease and Occurrence of Interstitial Lung Disease (ILD) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
1217
Severe Fibrosis and Increased Expression of Fibrogenic Cytokines in the Gastric Wall of Systemic Sclerosis Patients
1218
Autoantibody against Peroxiredoxin I, an Antioxidant Enzyme, in Patients with Systemic Sclerosis: Possible Association with Oxidative Stress
1219
Anti-p53 Antibody is a Novel Autoantibody Related to Limited Cutaneous Systemic Sclerosis
1220
Autoantibody Against One of the Antioxidant Repair Enzymes, Methionine Sulfoxide Reductase A (MSRA), in Systemic Sclerosis: Association with Pulmonary Fibrosis and Vascular Damage
1221
Autoantibody Profile In Systemic Sclerosis: Clinical Significance.
1222
The Use of Non-Steroidal Anti-Inflammatories in Systemic Sclerosis
1223
Clinical Improvement in Systemic Sclerosis Patients Treated with Anti-CD20
1224
Platelet Gel in the Treatment of Severe Scleroderma Skin Ulcers
1225
Inhaled Iloprost for the Treatment of Raynaud's Phenomenon
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>